Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us
Sectors and research

Generic medicine manufacturers

Generic and biosimilar medicines, produced at high volumes and typically sold at lower prices than original brands, have the potential to revolutionise the healthcare industry. At the Foundation, we engage generic medicine manufacturers to expand access and ensure these essential medicines reach those who need them most.
Event

Joint event with World Economic Forum on the evolving role of generics – Meeting Report

21 June 2023
Media

Poor countries desperately need better access to generic medicines

15 February 2023
Research

Workshop on expanding access to generic medicine – Meeting Report

12 May 2022
Featured News

Spotlight on the generics industry: New analysis looks at access efforts of 5 major companies

26 September 2023

How we work to mobilise generic and biosimilar medicine manufacturers

By applying our proven model for change, we stimulate major players to take action and bring together experts from the generics industry and beyond to explore strategies for improving access. As part of this effort, our newly established Generic & Biosimilar Medicines Programme focuses on mobilising these crucial companies and ensuring they realise their full potential as key players in expanding access to medicine.

In February 2023, we released a pioneering Analytical Framework to evaluate companies' efforts to expand access to essential medicines. Using this Framework, we published a milestone report in September 2023 that marks the first time we've spotlighted the access efforts of generic and biosimilar medicine manufacturers. The report features tailored company profiles of five leading manufacturers - Cipla, Hikma, Sun Pharma, Teva, and Viatris - summarising their commitments, strategies and activities to enhance the availability and affordability of their products in LMICs. Additionally, it presents key findings that illuminate industry-wide practices and offers specific recommendations for these companies to substantially improve their efforts.

The Foundation launched the report in Mumbai and London with events tailored to different stakeholders and designed to maximise the impact of the findings.

Publications

Read more in our Strategic Direction 2022-2026.

Read more

Catalysing industry-wide change for global access

As part of the Programme, we also leverage the Foundation’s convening power to bring the right people together to share insights and identify solutions. In May 2023, we held a joint event with the World Economic Forum to facilitate a dialogue on the evolving role of the generics and biosimilars industry in ensuring equitable access to medicines globally. This event, held alongside the 76th World Health Assembly in Geneva, attracted around 60 high-level participants, including CEOs, experts in medicine development and production, policymakers, representatives from non-profit organisations, and several leading manufacturers and regulators based in LMICs.

In addition, we mobilise generic medicine manufacturers to address specific challenges through our other cross-sector research programmes and streams. For example, since 2017, we have been tracking and assessing some of the world's largest generic medicine manufacturers as part of the Antimicrobial Resistance (AMR) Benchmark, looking at how they perform in addressing AMR and ensuring access to antimicrobial products such as antibiotics and antifungals.

Claudia Martínez

Director of Research

cmartinez@accesstomedicinefoundation.org

Get in touch

Explore our research sectors

R&D-based pharma companies

We influence and encourage them to make their products accessible for all.

Discover more

Generic medicine manufacturers

We empower the industry to become more responsive.

Discover more

Medical gas companies

We stimulate the industry to ensure availability for treatments and procedures.

Discover more

Diagnostic companies

We forge partnerships to unlock the potential of diagnostics.

Discover more

Vaccine manufacturers

We guide them to improve access to immunisation.

Discover more

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved